Loading clinical trials...
Loading clinical trials...
Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers
Conditions
Interventions
Nivolumab
Ipilimumab
+1 more
Locations
1
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Start Date
January 15, 2019
Primary Completion Date
November 5, 2022
Completion Date
November 5, 2023
Last Updated
December 29, 2023
NCT04693377
NCT04704661
NCT05235165
NCT04489719
NCT05039632
NCT03942653
Lead Sponsor
University of Washington
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions